A Phase 3 interventional study of AT-007 in Classic Galactosemia, sponsored by Applied Therapeutics, Inc.. Status unknown at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-06-14.
Sponsored by Applied Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a 12-month open-label extension (OLE) study of AT-007 in adult subjects with CG who previously participated in Study AT-007-1001 Part D and/or Part D Extension.
The study is designed to assess the long-term safety of AT-007 in subjects with CG as well as the pharmacodynamics (PD) (inhibition of galactitol) and PK of AT-007. The effect of 12-month treatment with AT-007 on the levels of galactose and other galactose metabolites in subjects with CG will also be evaluated.
Primary:
Secondary:
Exploratory:
Applied Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Open-label AT-007 20 mg/kg once daily
Drug: AT-007
AT-007 20 mg/kg once daily
To evaluate the long-term safety of 12-month oral administration of AT-007 in adult subjects with CG as assessed by adverse events.
Number of participants with treatment-emergent adverse events and broken down by organ class and relatedness.
Time frame: 12 months
To evaluate the long-term safety of 12-month oral administration of AT-007 in adult subjects with CG as assessed by clinical laboratory test results.
Number of participants with clinically-significant changes in clinical laboratory test results.
Time frame: 12 months
To evaluate the long-term safety of 12-month oral administration of AT-007 in adult subjects with CG as assessed by physical exam parameters.
Number of participants with clinically-significant changes in physical examination findings, vital sign abnormalities, and electrocardiogram findings.
Time frame: 12 months
To evaluate the long-term change of galactitol, a biomarker of AR activity, induced by 12-month oral administration of AT-007 to adult subjects with CG
Time frame: 12 months
To evaluate the pharmacokinetic (PK) parameter maximum concentration (Cmax) of 12-month oral administration of AT-007 in adult subjects with CG
Maximum concentration will be determined by individual concentration time-data (mg/L)
Time frame: 12 months
To evaluate the pharmacokinetic (PK) parameter Area-Under-the-Curve (AUC) of 12-month oral administration of AT-007 in adult subjects with CG (mg*h/L)
Time frame: 12 months
To evaluate the effect of 12-month oral administration of AT-007 on the levels of galactose and its other metabolites in adult subjects with CG
Time frame: 12 months
To evaluate the burden of illness (BOI) of adult subjects with CG- Medical History
Narrative description of natural course of CG as extracted by chart review and physical exam findings noted in chart review including the baseline neurologic exam upon entering the clinical trial. (There are no units for a descriptive narrative of medical history)
Time frame: 12 months
To evaluate the burden of illness (BOI) of adult subjects with CG- NIH Motor Battery
NIH Motor Battery produces normalized percentile scores with higher scores being more normal. As an exploratory endpoint, changes in the score from baseline to month 12 will assessed.
Time frame: 12 months
To evaluate the burden of illness (BOI) of adult subjects with CG- Spiral Drawing Test
Spiral Drawing Test produces normalized percentile scores with higher scores being more normal. As an exploratory endpoint, changes in the score from baseline to month 12 will assessed.
Time frame: 12 months
To evaluate quality of life (QOL) measures of adult subjects with CG- PROMIS Emotional Distress questionnaire
The questionnaire assesses this function with higher scores relating to better function and may be used to compare over time for change from baseline to month 12. \[PROMIS: Patient Reported Outcome Measure Information System\]
Time frame: 12 months
To evaluate quality of life (QOL) measures of adult subjects with CG- PROMIS Emotional Support questionnaire
The questionnaire assesses this function with higher scores relating to better function and may be used to compare over time for change from baseline to month 12. \[PROMIS: Patient Reported Outcome Measure Information System\]
Time frame: 12 months
To evaluate quality of life (QOL) measures of adult subjects with CG- PROMIS Companionship questionnaire
The questionnaire assesses this function with higher scores relating to better function and may be used to compare over time for change from baseline to month 12. \[PROMIS: Patient Reported Outcome Measure Information System\]
Time frame: 12 months
To evaluate quality of life (QOL) measures of adult subjects with CG- PROMIS Social Isolation questionnaire
The questionnaire assesses this function with higher scores relating to better function and may be used to compare over time for change from baseline to month 12. \[PROMIS: Patient Reported Outcome Measure Information System\]
Time frame: 12 months
To evaluate quality of life (QOL) measures of adult subjects with CG- PROMIS Ability to Participate in Social Roles and Activities questionnaire
The questionnaire assesses this function with higher scores relating to better function and may be used to compare over time for change from baseline to month 12. \[PROMIS: Patient Reported Outcome Measure Information System\]
Time frame: 12 months
Started Oct 2021 (actual). Primary completion is estimated for Nov 2022, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Govorestat
Galactosemias
Applied Therapeutics, Inc.